Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer

BACKGROUND: Markers to predict the efficacy of bevacizumab treatment have been not fully validated in most cancers, including metastatic colorectal cancer (mCRC). The aim of this study was to investigate the potential role of lactate dehydrogenase (LDH) in predicting the survival benefit from first-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yin, Chenxi, Jiang, Chang, Liao, Fangxin, Rong, Yuming, Cai, Xiuyu, Guo, Guifang, Qiu, Huijuan, Chen, Xuxian, Zhang, Bei, He, Wenzhuo, Xia, Liangping
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2014
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4136961/
https://ncbi.nlm.nih.gov/pubmed/25143746
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S64559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados